Skip to main

Blood supply and the purpose of repair

The ingredients in a KLOW peptide stack

Four names share the blend, but their biological histories go in different directions. The shorter TB-500 fragment makes the identity question especially consequential.

BPC-157: a gastric-juice sequence

BPC-157 is a synthetic peptide based on a partial sequence of a protein found in human gastric juice. It was originally developed for inflammatory bowel disease under the research name PL 14736. The KLOW peptide stack draws much of its tissue-repair rationale from later animal work.

In rats with fully transected Achilles tendons, BPC-157 improved biomechanical and functional recovery and collagen organisation. The vessel-tone experiments add another kind of result. A substance can alter the vascular environment while the question of benefit in an injured person remains unanswered.

I prefer knowing where the sequence came from to calling it a “healing peptide,” which assigns a broad job before a treatment has been tested.

GHK-Cu’s copper complex

GHK was first isolated from human plasma by Loren Pickart in 1973. GHK-Cu is the copper complex of that tripeptide. The 2015 skin-regeneration review brings together cell work and human topical findings, including increased collagen production.

The 2018 gene-data review describes changes in cell gene expression associated with tissue remodelling, protein quality control, antioxidant activity and DNA repair. Its gene counts describe changes in cellular instructions. A clinical outcome has to be measured separately.

The SPARC work offers a different origin for related fragments: breaking down a tissue protein released peptides that stimulated angiogenesis in cell and animal experiments. That is the sort of untidiness I enjoy. Repair biology includes releasing and removing material as well as producing it.

KPV: the inflammatory signal

KPV is a tripeptide taken from the end of alpha-melanocyte-stimulating hormone. In cultured human intestinal and immune cells, KPV reduced inflammatory signalling. Oral KPV also reduced the severity of experimental colitis in mice.

The transport protein PepT1 helped those cells take up KPV. I regard that uptake mechanism as useful specificity: the ingredient’s activity was studied in a particular cellular setting. It leaves open whether the same contribution helps a tendon-focused blend.

The KPV hydrogel papers explore local anti-inflammatory, antibacterial and wound-healing effects in cell and animal models and stabilisation and controlled release of KPV. Those preparations deserve their own descriptions rather than being absorbed into a generic claim for KLOW.

TB-500 and thymosin beta-4

Full-length thymosin beta-4 contains 43 amino acids. The TB-500 fragment described here contains 7. The fragment corresponds to an actin-binding region; actin participates in the machinery that cells use to move.

The rat wound-healing results used the full-length protein, as did the VEGF expression experiments. A review of hair-follicle biology also concerns thymosin beta-4. Those findings establish which substance was studied. They do not settle which activities the shorter fragment retains in a blend.

For me, that change in length rules out the casual substitution of names. A recognisable piece of a protein can justify further investigation, while the effects of the complete protein still need to be demonstrated for that piece.

Bars compare 43 amino acids in full-length thymosin beta-4 with 7 in the TB-500 fragment
Sequence lengths shown to scale. The wound and VEGF studies discussed above tested full-length thymosin beta-4; these lengths do not compare biological activity.